Literature DB >> 16918923

Nonparametric statistical methods for cost-effectiveness analyses.

Phillip Dinh1, Xiao-Hua Zhou.   

Abstract

Two measures often used in a cost-effectiveness analysis are the incremental cost-effectiveness ratio (ICER) and the net health benefit (NHB). Inferences on these two quantities are often hindered by highly skewed cost data. In this article, we derive the Edgeworth expansions for the studentized t-statistics for the two measures and show how they could be used to guide inferences. In particular, we use the expansions to study the theoretical performance of existing confidence intervals based on normal theory and to derive new confidence intervals for the ICER and the NHB. We conduct a simulation study to compare our new intervals with several existing methods. The methods evaluated include Taylor's interval, Fieller's interval, the bootstrap percentile interval, and the bootstrap bias-corrected acceleration interval. We found that our new intervals give good coverage accuracy and are narrower compared to the current recommended intervals.

Mesh:

Year:  2006        PMID: 16918923     DOI: 10.1111/j.1541-0420.2006.00509.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome.

Authors:  Jaime Latour-Perez; Eva de-Miguel-Balsa
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Median-Based Incremental Cost-Effectiveness Ratio (ICER).

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2012-08-10

Review 4.  Review of statistical methods for analysing healthcare resources and costs.

Authors:  Borislava Mihaylova; Andrew Briggs; Anthony O'Hagan; Simon G Thompson
Journal:  Health Econ       Date:  2010-08-27       Impact factor: 3.046

5.  Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling.

Authors:  Tamlyn Rautenberg; Claire Hulme; Richard Edlin
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-11

6.  Receptor conversion in metastatic breast cancer: a prognosticator of survival.

Authors:  Xiangying Meng; Santai Song; Ze-fei Jiang; Bing Sun; Tao Wang; Shaohua Zhang; Shikai Wu
Journal:  Oncotarget       Date:  2016-11-01

7.  Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.

Authors:  Ambica Parmar; Tina Jiao; Ronak Saluja; Kelvin K W Chan
Journal:  Cancer Med       Date:  2019-11-11       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.